Bristol Myers Squibb stock holds steady as new dividend and Opdivo lawsuit shape outlook
Published on 09/16/2026 at 14:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock (ISIN US0897961004) most recently finished the September 15, 2026 session at USD 63.69 on the New York Stock Exchange, down 0.64% from the prior close in regular trading according to MarketBeat data, leaving investors weighing a fresh dividend declaration and a new Opdivo-related lawsuit as trading resumes.
Dividend decision supports income profile
According to StockTitan on September 16, 2026, Bristol Myers Squibb's Board of Directors declared a quarterly dividend of USD 0.63 per share on its common stock, payable on November 2, 2026 to shareholders of record as of October 2, 2026.
As GuruFocus reported on September 16, 2026, the USD 0.63 quarterly dividend corresponds to a forward dividend yield of about 3.95% based on the prevailing share price, underlining Bristol Myers Squibb's appeal for income-oriented investors at current levels.
Historically, Bristol Myers Squibb has maintained this USD 0.63 per share dividend in recent quarters, so keeping the payout unchanged while the stock trades in the low USD 60s effectively stabilizes the yield profile despite moderate price fluctuations.
Opdivo biosimilar lawsuit adds legal uncertainty
Beyond the dividend, a fresh legal step in the company’s immuno-oncology franchise is shaping sentiment. As Feedzop summarized on September 16, 2026, Bristol Myers Squibb and its partner Ono Pharmaceutical filed a lawsuit in Delaware federal court on September 15, 2026 against Amgen, seeking to block a proposed U.S. biosimilar version of Opdivo.
Per Guavy on September 16, 2026, the lawsuit aims to protect Opdivo, a key cancer immunotherapy drug, from competition by challenging Amgen’s efforts to bring a biosimilar to market, highlighting the strategic importance of intellectual property for Bristol Myers Squibb’s long-term earnings.
For investors, this legal move introduces a tangible risk factor alongside the supportive dividend: while defending Opdivo could help preserve future revenue streams, litigation outcomes and potential settlement scenarios remain uncertain and may influence how analysts model cash flows in the immuno-oncology segment.
Earnings beat and guidance frame expectations
According to MarketBeat data cited in recent overviews, Bristol Myers Squibb’s latest reported quarterly results, announced on July 30, 2026, showed non-GAAP earnings per share of USD 2.04 compared with a consensus estimate of USD 1.60, representing an EPS beat of USD 0.44 or about 27.5% above expectations for that quarter.
The same MarketBeat summary indicates that revenue in that quarter reached USD 12.97 billion, with revenue up 5.7% on a year-over-year basis, underscoring that the company is still managing to expand its top line despite competitive pressures in key therapeutic areas.
In addition, MarketBeat notes that Bristol Myers Squibb has set fiscal 2026 non-GAAP EPS guidance in a range of USD 6.75 to USD 7.00 per share, while the consensus forecast currently stands at around USD 6.95, effectively in the middle of that range; this alignment shows that analysts broadly expect the company to deliver on its stated earnings framework for the year.
Analyst views and valuation context
Recent analyst commentary reflects a moderately constructive stance. As highlighted by MarketBeat data summarized in recent coverage, Bristol Myers Squibb stock carries a consensus rating of Moderate Buy with an average price target around USD 66.33, implying a modest upside versus the September 15, 2026 closing level of USD 63.69.
According to a Futunn-based overview cited in the same context, RBC Capital maintains Bristol Myers Squibb at Hold with a target price of USD 64, which is very close to the mid-USD 60s price range seen in mid-September 2026 and suggests that at least some analysts view the shares as fairly valued near current levels.
GuruFocus on September 16, 2026 argues that Bristol Myers Squibb appears about 12.7% overvalued relative to its proprietary GF Value metric while the stock offers a 3.95% dividend yield, indicating that valuation opinions vary depending on methodology even as the income component remains a stable part of the investment case.
Stock price level and trading metrics
Per MarketBeat’s price data snapshot for Bristol Myers Squibb on September 15, 2026, the shares closed at USD 63.69 on the New York Stock Exchange, down 0.64% on the day and trading in a relatively narrow intraday band between roughly USD 63 and USD 64 in a softer U.S. equity market environment.
Earlier, NYSE closing data relayed by MarketBeat showed that Bristol Myers Squibb stock had closed at USD 64.08 on September 14, 2026, up 0.69% versus the prior session and about USD 2.25, or roughly 3.5%, below the prevailing analyst consensus target of USD 66.33, illustrating how the stock has been moving slightly below its average Wall Street objective.
MarketBeat's overview also lists Bristol Myers Squibb’s market capitalization at around USD 130.9 billion as of September 14, 2026, giving investors a sense of the company’s scale in the global biopharmaceutical sector and the potential impact of any major legal or pipeline developments on shareholder value.
Bristol Myers Squibb stock: price snapshot
As of the most recent completed session on September 15, 2026, Bristol Myers Squibb stock closed at USD 63.69 on the New York Stock Exchange, down 0.64% from the prior close, with a market capitalization reported at approximately USD 130.9 billion as of September 14, 2026 and the shares trading a few dollars below the average analyst price target around USD 66.33.
Bristol Myers Squibb stock at a glance
- Company: Bristol Myers Squibb Company
- ISIN: US0897961004
- Ticker: BMY
- Trading venue: NYSE
- Price (as of September 15, 2026): 63.69 USD
- Market capitalization: 130.9 billion USD (as of September 14, 2026)
- Sector / Industry: Pharmaceuticals / Biopharmaceuticals
- Index membership: S&P 500
